The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.
October 25, 2018
Full of our informative publications, including our Patient Handbook and selections from the popular Understanding Series, the Info Pack will…
January 09, 2023
This publication discusses the use of ABECMA® (idecabtagene vicleucel), the first CAR T-cell therapy to be approved by the FDA for patients with…
January 21, 2021
Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate (ADC), the first in a new class of treatments for myeloma. Blenrep is the…
June 29, 2022
Carvykti™ (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of adult…
July 03, 2018
This publication discusses what myeloma patients should consider if enrolling in a clinical trial.
We Thank Our Sponsors:
BMS, GSK, Janssen, Karyopharm Therapeutics, Legend Biotech, Sanofi, and Takeda Pharmaceuticals U.S.A., Inc.